Annita Tanini Sells 1,224 Shares of Keros Therapeutics (NASDAQ:KROS) Stock
Annita Tanini, VP at Keros Therapeutics, sold 1,224 shares of KROS stock worth $12,594.96 to cover tax withholding obligations on August 18th, 2026, reducing her stake by 2.64%. This insider sale comes amidst weak financial results, with the company missing earnings estimates and analysts projecting a full-year loss of $5.16 per share. Despite institutional ownership of 71.56% and an average analyst target of $20.50, the stock is trading significantly lower at $10.95, with mixed analyst ratings.
Lorena Raquel Lerner Sells 3,568 Shares of Keros Therapeutics (NASDAQ:KROS) Stock
Lorena Raquel Lerner, an insider at Keros Therapeutics (NASDAQ:KROS), sold 3,568 shares for $36,714.72 to cover tax withholding obligations related to vested equity awards, reducing her ownership by 11.46%. The company is facing weak financial performance with a recent quarterly loss and its stock trading near a 12-month low. Analyst ratings are mixed, with a consensus "Hold" and an average target price of $20.50.
Keros Therapeutics (NASDAQ: KROS) director schedules 551-share sale
Keros Therapeutics (NASDAQ: KROS) director Charles W. Newton has filed a Form 144 to sell 551 shares of common stock through UBS Financial Services Inc. These shares are related to restricted stock units (RSUs) with an indicated date of August 15, 2026. The filing also notes a previous sale of 550 shares on June 11, 2026.
Keros Therapeutics (NASDAQ:KROS) Lowered to Strong Sell Rating by Wall Street Zen
Keros Therapeutics (NASDAQ:KROS) has been downgraded to a "strong sell" rating by Wall Street Zen. This comes as the company's shares opened near their 52-week low and reported a larger-than-expected quarterly loss of $1.45 per share. Despite the downgrade, the broader analyst consensus for KROS remains "Hold" with an average price target of $20.50, and institutional investors hold a significant portion of the stock.
Keros Therapeutics, Inc. $KROS Shares Acquired by Dimensional Fund Advisors LP
Dimensional Fund Advisors LP significantly increased its stake in Keros Therapeutics (NASDAQ:KROS) by 453.9% in the first quarter, now owning 1.62% of the company. Despite this institutional interest, Keros Therapeutics missed analyst expectations with a quarterly loss of $1.45 per share, and its stock remains well below its 52-week high. Analyst sentiment is mixed, with a consensus "Hold" rating, while company insiders have sold shares worth nearly $90,000 in the last 90 days.
Keros Therapeutics, Inc. Stock 12‑Month Price Target Cut to $19.83, Implies 86% Upside
Analysts have lowered the 12-month average price target for Keros Therapeutics, Inc. (KROS) stock from $20.33 to $19.83, with individual forecasts ranging from $16 to $25 per share. Despite the cut, this new target still suggests an 86% potential upside based on the Aug. 10 closing price. The consensus rating for KROS remains "Buy" among 8 analysts.
Keros Therapeutics, Inc. (NASDAQ:KROS) Given Average Rating of "Hold" by Analysts
Keros Therapeutics (NASDAQ:KROS) has received an average "Hold" rating from analysts, with nine analysts providing coverage: four buy, three hold, and two sell recommendations. The average 12-month price target is $20.50, significantly higher than its current $11.15 price. Despite this, the company reported weaker-than-expected quarterly EPS of negative $1.45 and expects a full-year loss of $5.12 per share, while insiders have been selling shares, even as institutional investors hold a majority stake.
Keros Therapeutics (NASDAQ:KROS) Raised to "Sell" at Wall Street Zen
Wall Street Zen has upgraded Keros Therapeutics (NASDAQ:KROS) from a "strong sell" to a "sell" rating, while other analysts remain divided with a consensus "Hold" rating and an average price target of $20.50. The company reported a Q2 EPS of -$1.45, missing estimates, and analysts anticipate a full-year loss of $5.12 per share. Insider transactions show recent sales, and institutional investors hold 71.56% of the stock as Keros continues developing therapies for anemia.
Renaissance Technologies LLC Sells 138,204 Shares of Keros Therapeutics, Inc. $KROS
Renaissance Technologies LLC has reduced its stake in Keros Therapeutics, Inc. by 23.4%, selling 138,204 shares and now owning 453,482 shares valued at approximately $5.0 million. This comes as Keros shares trade near their 52-week low, following a quarterly loss that missed analyst estimates and continued insider selling. Despite mixed analyst sentiment, with a consensus "Hold" rating and a $20.50 price target, the company faces challenges including unprofitability and dependence on future clinical progress.
FY2026 EPS Estimate for Keros Therapeutics Raised by Analyst
HC Wainwright has revised its FY2026 EPS estimate for Keros Therapeutics (NASDAQ:KROS), forecasting a smaller loss of $4.62 per share, an improvement from their previous estimate of a $5.12 loss. Despite this, the company faces mixed analyst sentiment with a consensus "Hold" rating and an average price target of $20.50, as several firms have recently lowered targets or downgraded the stock. Keros Therapeutics reported a quarterly loss of $1.45 per share, missing the consensus estimate, and has seen insider selling activity in recent months, though institutional investors hold a significant stake.
KROS Q2 Earnings Miss as Revenues Fall to Zero, Pipeline in Focus
Keros Therapeutics (KROS) reported a Q2 2026 loss of $1.45 per share, wider than anticipated, with revenues falling to zero as the company has no marketed product. Despite the lack of revenue, Keros maintains a cash runway into the first half of 2028, supporting the development of its lead candidate, rinvatercept, which is in phase II trials for Duchenne muscular dystrophy and is also being explored for amyotrophic lateral sclerosis. The company's expenses decreased significantly due to a corporate restructuring and the transfer of development costs for another candidate, elritercept, to Takeda.
TD Cowen Maintains Keros Therapeutics(KROS.US) With Hold Rating
TD Cowen has reiterated its Hold rating on Keros Therapeutics (KROS.US). The article does not provide further details or a price target for the stock.
Keros Therapeutics, Inc. Stock 12‑Month Price Target Cut to $20.33, Implies 101% Upside
Keros Therapeutics, Inc.'s stock average price target has been reduced from $21.83 to $20.33 by 6 analysts, with a range of $16 to $25 per share. This new target suggests a potential 101% upside based on the August 3 closing price. The consensus rating for Keros Therapeutics remains "Buy" from 8 analysts.
KEROS THERAPEUTICS INC : LEERINK PARTNERS CUTS TARGET PRICE TO $23 FROM $30
Leerink Partners has reduced its target price for Keros Therapeutics Inc (KROS.O) from $30 to $23. This adjustment reflects an analyst's revised outlook for the company. The article, sourced from Reuters, does not provide further details on the reasons behind the target price cut.
Keros Therapeutics (NASDAQ:KROS) Announces Quarterly Earnings Results, Misses Estimates By $0.20 EPS
Keros Therapeutics (NASDAQ:KROS) announced its quarterly earnings, reporting a loss of $1.45 per share, which missed the consensus estimate by $0.20. The company also posted negative returns on equity and net margin. KROS shares are trading near their one-year low, and analysts maintain a "Hold" rating with a target price of $20.40.
Leerink Partners Maintains Keros Therapeutics(KROS.US) With Buy Rating, Cuts Target Price to $23
Leerink Partners has reiterated its Buy rating for Keros Therapeutics (KROS.US) but has lowered its target price to $23. This adjustment reflects the firm's updated valuation for the biopharmaceutical company.
H.C. Wainwright Maintains Keros Therapeutics(KROS.US) With Buy Rating, Maintains Target Price $20
H.C. Wainwright has reiterated its Buy rating on Keros Therapeutics (KROS.US) and maintained its target price of $20. This indicates a continued positive outlook from the firm regarding the company's stock performance.
KEROS THERAPEUTICS INC : LEERINK PARTNERS CUTS TARGET PRICE TO $23 FROM $30
Leerink Partners has reduced its target price for Keros Therapeutics Inc. (KROS.O) from $30 to $23. The article is a brief news flash from Reuters, indicating a significant change in analyst outlook for the company's stock.
Keros Therapeutics (NASDAQ:KROS) Price Target Lowered to $23.00 at Leerink Partners
Leerink Partners has lowered its price target for Keros Therapeutics (NASDAQ:KROS) to $23.00 from $30.00, while maintaining an "outperform" rating, suggesting a potential upside of 127.5% from its previous close. The company recently missed consensus earnings estimates, reporting a quarterly loss of $1.45 per share against an expected $1.25 loss. Despite a mixed analyst sentiment with an average "Hold" rating and a target of $20.83, insider selling and a stock price near its 52-week low indicate challenges.
KEROS THERAPEUTICS INC : LEERINK PARTNERS CUTS TARGET PRICE TO $23 FROM $30
Leerink Partners has lowered its target price for Keros Therapeutics Inc. (KROS.O) from $30 to $23. This adjustment reflects an updated outlook on the company's financial prospects or market valuation.
Keros Therapeutics 2026: Revenue $0 EPS ($1.45) — 10-Q Summary
Keros Therapeutics reported zero revenue and a net loss of ($28.71M) for the 2026 quarter, resulting in a diluted EPS of ($1.45). This decline is attributed to a transition of partnered activities to Takeda, which also led to reduced R&D and G&A spending. The company's cash runway is projected to last into the first half of 2028, supporting ongoing clinical programs.
Keros Therapeutics posts $28.7 million second quarter net loss
Keros Therapeutics (KROS) reported a Q2 2026 net loss of $28.7 million, an improvement from a $30.7 million loss in Q2 2025, with no total revenue for the quarter. The company initiated a Phase 2 clinical trial for rinvatercept and expects initial data in the first half of 2027, with sufficient cash and cash equivalents of $257.6 million to fund operations into the first half of 2028. Insider trading shows more sales than purchases over the past six months, while institutional investors had mixed activity with 56 increasing and 87 decreasing their positions.
Keros Therapeutics Reports Second Quarter 2026 Financial Results
Keros Therapeutics announced its Q2 2026 financial results, reporting a net loss of $28.7 million, an improvement from $30.7 million in Q2 2025. The company also provided a business update, including the initiation of a Phase 2 clinical trial for rinvatercept in Duchenne muscular dystrophy and expectations for data in H1 2027. Keros projects its current cash and cash equivalents of $257.6 million will fund operations into the first half of 2028.
Arrowstreet Capital Limited Partnership Sells 744,267 Shares of Keros Therapeutics, Inc. $KROS
Arrowstreet Capital Limited Partnership reduced its stake in Keros Therapeutics, Inc. by 55.8% in the first quarter, selling 744,267 shares and retaining 590,249 shares valued at $6.52 million. Several other institutional investors adjusted their positions, with some increasing and others purchasing new stakes. Company insiders also sold shares, while analysts have issued mixed ratings, with an average "Hold" and a price target of $20.40.
Keros Therapeutics (NASDAQ:KROS) Lowered to Strong Sell Rating by Zacks Research
Zacks Research has downgraded Keros Therapeutics (NASDAQ:KROS) to a "strong sell" rating, citing weaker-than-expected quarterly results where the company missed both earnings per share and revenue estimates. The stock is trading near its 52-week low, and company insiders have recently sold a significant amount of shares. Institutional investors, however, hold a majority stake in the biopharmaceutical company which focuses on therapies for erythropoiesis and iron regulation disorders.
Keros Therapeutics Inc (KROS) Institutional Confidence
Keros Therapeutics Inc (KROS) has an institutional shareholding score of 10.00, placing it first in the Biotechnology & Medical Research industry. The institutional shareholding proportion has increased by 16.94% quarter-over-quarter, reaching 114.30%. James Simons is the largest institutional shareholder, holding 2.30% of outstanding shares.
Keros Therapeutics to Receive $20M Development Milestone Payment From Takeda
Keros Therapeutics is set to receive a $20 million development milestone payment from Takeda Pharmaceutical Company. This payment follows Takeda's decision to advance one of Keros's novel investigational compounds into a Phase 1 clinical trial for the treatment of a rare hematological disease. The collaboration between the two companies focuses on developing therapies for rare hematological and oncological diseases.
Keros expects to distribute 25% of net cash proceeds after Takeda payment
Keros Therapeutics will receive a $20 million development milestone payment from Takeda, triggered by the first patient dosing in the Phase 3 ELRiSE MDS trial for elritercept. This payment is part of a global license agreement that includes a prior $200 million upfront payment and potential future milestones exceeding $1.1 billion. Keros plans to distribute 25% of the net cash proceeds from this $20 million milestone to its stockholders.
Keros Therapeutics to Receive $20M Milestone After First ELRiSE MDS Patient Dosed
Keros Therapeutics is set to receive a $20 million milestone payment from Takeda after the first patient was dosed in the Phase 3 ELRiSE MDS trial. This payment is part of a larger global license agreement that included a $200 million upfront payment and potentially over $1.1 billion in additional milestones, plus royalties. Keros plans to distribute 25% of the net cash proceeds from this specific milestone to its stockholders.
BlackRock (KROS holder) discloses 1.67M-share, 8.4% stake in Keros Therapeutics
BlackRock, Inc. has disclosed a beneficial ownership stake of 8.4% in Keros Therapeutics, Inc. (KROS), totaling 1,671,343 shares of common stock as of June 30, 2026. The filing indicates BlackRock holds sole voting power over 1,645,352 shares and sole dispositive power over all 1,671,343 shares, with no shared powers. This disclosure, made via a Schedule 13G/A filing, confirms BlackRock's significant but passive investment in the biotechnology company.
Keros Therapeutics (KROS) Projected to Post Earnings on Wednesday
Keros Therapeutics (KROS) is expected to report its Q2 2026 earnings before market open on Wednesday, August 5th, with analysts forecasting a loss of $1.25 per share and revenue of $807,000. This follows its previous quarter where the company missed expectations, reporting a $1.21 per-share loss against a $1.02 estimate and revenue of $370,000 against $1.93 million. KROS shares opened near their 12-month low, and insiders have recently sold shares worth approximately $90,000.
Keros Therapeutics Inc (KROS) Financial Health: Profitability & Balance Sheet Analysis
Keros Therapeutics Inc (KROS) has a financial score of 6.25, placing it 274th out of 386 in the Biotechnology & Medical Research industry, indicating a robust financial status despite low operating efficiency. The company's latest quarterly revenue decreased by 99.83% year-over-year, and its net profit fell by 115.97% year-over-year. Key financial metrics such as total assets, liabilities, and free cash flow have not been disclosed by the company.
Keros Therapeutics Inc (KROS) Dividends & Stock Splits: Historical Payouts and Event Timeline
The article provides an overview of Keros Therapeutics Inc (KROS) focusing on its dividend and stock split history. It states that Keros Therapeutics has not distributed any dividends over the past five years and contains no data regarding historical payouts or event timelines. Financial data like market cap and current stock price are included.
Keros Therapeutics Inc (KROS) Shareholder Structure: Major Shareholders & Institutional Holdings
This article provides a detailed breakdown of Keros Therapeutics Inc (KROS) shareholder structure, listing major shareholders and their proportional holdings. It also outlines the types of shareholders, institutional shareholding trends over several quarters, and recent shareholder activity with changes in holdings for key investors. Additionally, the article identifies related ETFs that hold KROS stock.
Keros Therapeutics Inc (KROS) Cash Flow
This article provides the cash flow statements for Keros Therapeutics Inc (KROS), including operating, investing, and financing activities, presented in both quarterly and annual formats. It details various components of cash flow, such as net income, changes in working capital, capital expenditures, and stock issuance. The comprehensive data allows for an evaluation of the company's financial health and stability.
Keros Therapeutics, Inc. Revenue Breakdown – NASDAQ:KROS
Keros Therapeutics, Inc. (NASDAQ: KROS) generated $244.06 million USD in revenue last year, primarily from its Novel Therapeutics segment. This marks a significant increase from $3.55 million USD in the previous year. The United States was the greatest contributor to its revenue.
KROS|Keros Therapeutics Inc|Price:10.060|Chg%:-0.080
This article provides a financial overview of Keros Therapeutics Inc (KROS), detailing its stock performance, key financial indicators, and historical financial statements (Income Statement, Balance Sheet, Cash Flow Statement). It highlights the company's recent earnings report, showing total revenue of $244.06M and an EPS of $2.34 for FY2025, with analysis of quarterly and annual data. The article also includes FAQs regarding Keros Therapeutics Inc's financial metrics.
KROS|Keros Therapeutics Inc|Price:10.060|Chg%:-0.080
Keros Therapeutics Inc. (KROS) is currently trading at $10.06, down 0.79%, with a market cap of $198.51M. The company, a clinical-stage biopharmaceutical firm, focuses on developing therapeutics for disorders linked to dysfunctional TGF-B signaling. Analysts currently rate KROS as "Buy" with a target price of $21.83, despite recent sideways trading and a weak stock market performance over the last month.
Keros Therapeutics CFO Keith Regnante resigns effective Aug. 3
Keros Therapeutics announced that its Chief Financial Officer, Keith Regnante, has resigned, with his departure effective August 3. Annita Tanini, the current Vice President of Finance, has been appointed as the interim principal financial officer to maintain continuity. This leadership transition was disclosed in a regulatory filing to the SEC.
Keros Therapeutics (NASDAQ: KROS) names interim finance and accounting head
Keros Therapeutics (NASDAQ: KROS) has announced that its Chief Financial Officer, Keith Regnante, will resign effective August 3, 2026. Annita Tanini, currently Corporate Controller and Vice President, Finance, has been appointed interim principal financial and accounting officer starting August 4, 2026, while the company searches for a new CFO. Ms. Tanini's new compensation package includes an annual base salary of $302,300 and eligibility for a 30% annual cash bonus.
Discipline and Rules-Based Execution in KROS Response
This article analyzes Keros Therapeutics Inc. (NASDAQ: KROS) with AI-generated trading strategies. It identifies a near-term weak sentiment, suggesting a potential resumption of long-term weakness, and highlights an exceptional 103.7:1 risk-reward short setup. The piece provides specific entry, target, and stop-loss levels for position, momentum breakout, and risk hedging strategies, based on multi-timeframe signal analysis.
Keros Therapeutics (KROS) director adds 1,000 shares under 10b5-1 plan
Keros Therapeutics director Jean Jacques Bienaime purchased 1,000 shares of KROS common stock on July 15, 2026, at a weighted-average price of $10.61 per share. This transaction was conducted under a Rule 10b5-1 trading plan adopted in December 2025, increasing his direct holdings to 18,592 shares. The purchase, valued at $10,610, involved trades ranging from $10.46 to $10.80 per share.
KROS 2026 Watchlist: 3 Catalysts That Could Reset Sentiment
Keros Therapeutics (KROS) is entering 2026 with a focus on three key catalysts expected to reshape investor sentiment. These include the planned Q2 2026 phase II initiation of rinvatercept in Duchenne muscular dystrophy, regulatory discussions for rinvatercept in ALS in the second half of 2026, and continued progress in Takeda's phase III RENEW study for elritercept. These milestones aim to validate management's execution, broaden the pipeline's perceived opportunity, and preserve upside through milestone payments despite the volatility of non-recurring revenue.
KROS Stock: Does the Takeda Deal Lower Dilution Risk in 2026?
Keros Therapeutics (KROS) significantly reshaped its financial profile in 2025 through a major licensing deal with Takeda for elritercept, leading to a surge in revenue and a reduction in R&D expenses. While this extended Keros' cash runway into the first half of 2028 and reduced its share count through capital returns, the uncertainty of future milestone payments means dilution risk for 2026 remains a key concern. The company's valuation is currently anchored to its book value, and investors will be watching for stable operating expenses and pipeline execution.
BlackRock Portfolio Management (KROS) discloses 5.7% ownership in Keros Therapeutics
BlackRock Portfolio Management LLC has disclosed a 5.7% beneficial ownership in Keros Therapeutics, Inc., holding 1,122,874 shares of common stock. This information was reported via a Schedule 13G SEC filing, indicating BlackRock's passive investment intentions. The firm maintains sole voting power over 991,089 shares and sole dispositive power over all 1,122,874 shares, with no single underlying person owning more than five percent of Keros' outstanding common stock.
Insiders Sold Keros Therapeutics Prematurely At US$15.15 With Stock Trading Higher
Insiders at Keros Therapeutics sold shares at an average price of US$15.15 over the past year, before the stock price dropped 12% in the last week. Despite the recent dip, the current share price of US$10.61 is still below the average selling price, suggesting insiders might have sold prematurely. Insider selling has continued over the last three months with no corresponding purchases, which, coupled with relatively low insider ownership (3.2%), raises caution among investors.
Keros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Rating of "Hold" by Brokerages
Keros Therapeutics (NASDAQ:KROS) has received a consensus "Hold" rating from eight brokerages, with an average 12-month price target of $20.40. Recent analyst downgrades and a significant miss on latest quarterly earnings, with a loss of $1.21 per share and revenue of $0.37 million, have impacted the stock. Shares are trading near their 52-week low, and company insiders have been selling stock, although institutions still hold a large majority of the company.
Discipline and Rules-Based Execution in KROS Response
Keros Therapeutics Inc. (NASDAQ: KROS) is showing strong near and mid-term sentiment, but a weak long-term outlook. The article highlights an exceptional 107.3:1 risk-reward short setup and provides three distinct AI-generated trading strategies tailored to various risk profiles and holding periods, along with multi-timeframe signal analysis.
Form 4 Keros Therapeutics Inc For: 6 July By Investing.com
This article from Investing.com reports the filing of a Form 4 for Keros Therapeutics Inc. on July 6. Form 4 filings are typically used to report changes in beneficial ownership of securities by company insiders. The article includes the stock symbol KROS and its performance on that date.
Keros Therapeutics | DEFA14A: Others
This entry indicates that Keros Therapeutics has filed a DEFA14A document, which typically pertains to definitive additional soliciting materials filed with the SEC. These materials are often related to proxy solicitations and shareholder meetings. The specific contents within this filing are not detailed in the provided content.
